Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moxifloxacin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

NCT04563845
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 6, 2026, 11:22 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

NCT06574828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

AMS VS MOXI Ketek vs Avelox in AMS

NCT00537563
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
Telithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 6, 2026, 11:22 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109, SQ109 Placebo, Moxifloxacin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

NCT01296542
View directory record Official record
Conditions
Cataracts
Interventions
Moxifloxacin Ophthalmic, Besifloxacin Ophthalmic
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Oral Contraceptive DDI Study

NCT02494609
View directory record Official record
Conditions
Healthy
Interventions
sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Estetrol Monohydrate (E4) on QTc Interval

NCT04819906
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of Telotristat Etiprate

NCT02155205
View directory record Official record
Conditions
QT Interval
Interventions
Telotristat etiprate, Placebo, Moxifloxacin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

NCT01498861
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Ortho-Cyclen, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 4 Interventional

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

NCT00665327
View directory record Official record
Conditions
Pneumonia
Interventions
Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
Drug
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
76
States / cities
Mobile, Alabama • Tucson, Arizona • Brea, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

NCT01702376
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ondansetron, moxifloxacin, saline
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

NCT01913002
View directory record Official record
Conditions
Healthy
Interventions
LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 6, 2026, 11:22 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

NCT01090661
View directory record Official record
Conditions
Healthy
Interventions
mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 6, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 6, 2026, 11:22 AM EDT